Healthcare / Drug Manufacturers - GeneralSwiss
$113.90
-3.92 (-3.33%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 22% · confianza 25%
FCF escenarios
weak_data · normalized FCF $13.8B · quality 76.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
54/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$217.3B
P/E
20.7x
↑EV/EBITDA
10.6x
↓ROE
30.3%
↑Gross Margin
75.8%
↑Debt/Equity
0.77
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+9.3%
FCF CAGR
+8.3%
FCF margin
26.9%
FCF / Net income
1.09x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $56.67B · net income $13.98B · FCF $15.24B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $56.67B | $56.67B | $51.72B | $46.66B | $43.46B |
| Net Income | $13.98B | $13.98B | $11.94B | $14.85B | $6.96B |
| EBITDA | $22.82B | $22.82B | $20.71B | $18.25B | $14.68B |
| EPS | 7.15 | 7.15 | 5.87 | 7.10 | 3.17 |
| Gross Margin | 75.8% | 75.8% | 75.2% | 73.3% | 73.4% |
| Operating Margin | 31.1% | 31.1% | 28.1% | 20.9% | 18.3% |
| Net Margin | 24.7% | 24.7% | 23.1% | 31.8% | 16.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.77 | 0.77 | 0.71 | 0.56 | 0.47 |
| Current Ratio | 0.85 | 0.85 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $15.24B | $15.24B | $13.80B | $11.71B | $12.00B |
| Returns | |||||
| ROE | 30.3% | 30.3% | 27.1% | 31.8% | 11.7% |
| Valuation | |||||
| P/E | 20.71 | 20.71 | 15.52 | 12.73 | 25.64 |
| EV/EBITDA | 10.57 | 10.57 | 9.64 | 10.83 | 13.12 |
| P/B | 4.71 | 4.71 | 4.08 | 3.96 | 2.90 |
| Growth & Yield | |||||
| Revenue Growth | 9.6% | 9.6% | 10.8% | 7.4% | — |
| EPS Growth | 21.8% | 21.8% | -17.3% | 124.0% | — |
| Dividend Yield | 3.1% | 3.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
12.2%
EPS terminal req.
$10.11
Spread vs growth
9.6%
5Y implied EPS CAGR
11.3%
EPS terminal req.
$12.23
Spread vs growth
10.5%
10Y implied EPS CAGR
10.7%
EPS terminal req.
$19.70
Spread vs growth
11.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+24.6%
Start / end P/E
16.0x → 15.9x
EPS bridge
5.87 → 7.15
Residual
-0.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.